Circulating Tumour DNA (ctDNA) as a Predictor of Clinical Outcome in Non-Small Cell Lung Cancer Undergoing Targeted Therapies: A Systematic Review and Meta-Analysis

Circulating Tumour DNA (ctDNA) as a Predictor of Clinical Outcome in Non-Small Cell Lung Cancer Undergoing Targeted Therapies: A Systematic Review and Meta-Analysis

Background: Liquid biopsy (LB) analysis using (ctDNA)/cell-free DNA (cfDNA) is an emerging alternative to tissue profiling in (NSCLC). LB is used to guide treatment decisions, detect resistance mechanisms, and predicts responses, and, therefore, outcomes. This systematic review and meta-analysis eva...

Full description

Bibliographic Details
Main Authors: Farzana Y. Zaman, Ashwin Subramaniam, Afsana Afroz, Zarka Samoon, Daniel Gough, Surein Arulananda, Muhammad Alamgeer
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Cancers
Subjects:
non-small-cell lung cancer
NSCLC
liquid biopsy
circulating tumour DNA
ctDNA
progression-free survival
Online Access:https://www.mdpi.com/2072-6694/15/9/2425

Internet

https://www.mdpi.com/2072-6694/15/9/2425

Similar Items